New drug combo aims to stop liver cancer recurrence in transplant patients
NCT ID NCT02081755
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the drug everolimus can lower the risk of liver cancer coming back after a liver transplant in patients with high-risk hepatocellular carcinoma. About 336 adults who have just received a transplant will be randomly assigned to take everolimus plus tacrolimus or standard immunosuppressants. The main goal is to see how long patients live without their cancer returning.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Everolimus (also known as Zortress or Afinitor)
What this could lead to
If successful, this could point toward a way to lower the chance of liver cancer coming back after a transplant, helping patients live longer without recurrence.
What could go wrong
This is a phase 4 study, so the drug is already approved, but it's still uncertain if everolimus will outperform standard treatments. Risks include side effects like infections, kidney problems, and wound healing issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, HEPATOCELLULAR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor University Medical Center
Dallas, Texas, 75246, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Mount Sinai Medical Center
New York, New York, 10029, United States
-
Northwestern University School of Medicine
Chicago, Illinois, 60611, United States
-
University of California at San Francisco
San Francisco, California, 94143, United States
-
University of Kansas Medical Center
Kansas City, Kansas, 66160, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
University of Tennessee- Methodist University Hospital
Memphis, Tennessee, 38104, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States